The Global Health Body Raises Alert Over Acute Scarcity of Weight-Loss Medications
Under a tenth of patients eligible to benefit from obesity jabs such as Wegovy can access them, states the global health agency as it publishes its first guidance on the drugs.
Given more than one billion people worldwide now obese, it is calling for more widespread and fairer access to this class of drugs.
According to forecasts, more than two billion could be obese by 2030 without intervention.
"The latest guidance affirms that excess weight is a chronic disease that can be managed with holistic and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant hurdles to widespread availability to the injections that can assist patients in reducing significant body mass, says the body.
GLP-1 Therapy Scarcity
Despite the current most optimistic case, the supply of these medications could only cover approximately 100 million people – fewer than 10% of those who need them, according to the health organization.
The recommendation calls on countries and companies to increase availability, via approaches such as licensing agreements.
Exclusive production rights on a key compound – the core component of the drug Wegovy – is set to lapse in multiple nations in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users reduce food intake.
Individuals commonly see weight reduction after several weeks of commencing the once-weekly jabs.
Evidence indicates patients may put most of the weight back on within a year of stopping the treatment, as their normal hunger return.
To be carrying excess weight elevates your chance for contracting health problems, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight impacts individuals in every country and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.